Transplant; Complication, Failure Clinical Trial
Official title:
Evaluation of a Marine OXYgen Carrier (HEMO2Life®) for hypOthermic Kidney Graft Preservation Before Transplantation (OXYOP): 4 Years Follow-up
4 years follow-up of the oxyop study.
Oxyop (NCT02652520 PHRC) was a safety study evaluating the use of an oxygen carrier HEMO2life® as an additive in organ preservation solution in 60 transplanted kidneys. This was a national multicenter (6 centers) open-labeled safety study on HEMO2life® that included 58 recipients. The first patient was included on March 24th, 2016 and the study was completed on February 23th, 2018 (1 year of recruitment and 1 year of follow-up). We also analyzed some efficacy secondary end points using a paired analysis (local kidney receiving HEMO2life® versus contralateral kidney transplanted elsewhere in France). Oxyop4 aims to analyse 4 years results. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04848844 -
The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)
|
||
| Not yet recruiting |
NCT05469906 -
Evaluation at 5 and 10 Years of Renal Transplant Patients
|
||
| Completed |
NCT03893656 -
Retroperitoneoscopic Donor Nephrectomy
|